Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bydureon in adolescents with type 2 diabetes
NCT01554618Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2011
- Primary completion
- May 2020
- Modality
- Peptides
- Countries
- 7
01
Overview
A Phase 3 trial of exenatide extended-release in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Dec 2011; status: completed.
02
Drugs
exenatide extended-release
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01554618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01554618.